Metformin Hydrochloride

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

105 API Suppliers, 55 USDMF, 41 CEP/COS, 13 JDMF, 28 EU WC, 100 KDMF, 38 NDC API, 42 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

25 Drugs in Development

25 Drugs in Development

FINISHED DOSAGE FORMULATIONS

1812 FDF Dossiers, 416 FDA Orange Book, 545 Europe, 120 Canada, 102 Australia, 137 South Africa, 492 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 2.5MG BASE, TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 5MG BASE, TABLET, EXTENDED RELEASE;ORAL - 500MG;EQ 5MG BASE, TABLET;ORAL - 2.5MG;1GM, TABLET;ORAL - 2.5MG;500MG, TABLET;ORAL - 2.5MG;850MG, TABLET;ORAL - EQ 12.5MG BASE;1GM, TABLET;ORAL - EQ 12.5MG BASE;500MG, TABLET;ORAL - 1GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 625MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 750MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 850MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - 150MG;1GM, TABLET, EXTENDED RELEASE;ORAL - 150MG;500MG, TABLET, EXTENDED RELEASE;ORAL - 50MG;1GM, TABLET, EXTENDED RELEASE;ORAL - 50MG;500MG, TABLET;ORAL - 1.25MG;250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 2.5MG;500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 5MG;500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - 750MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, FOR SUSPENSION, EXTENDED RELEASE;ORAL - 500MG/5ML, TABLET, EXTENDED RELEASE;ORAL - 1GM, TABLET, EXTENDED RELEASE;ORAL - 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SOLUTION;ORAL - 500MG/5ML, TABLET, EXTENDED RELEASE;ORAL - 1GM, TABLET, EXTENDED RELEASE;ORAL - 500MG, TABLET;ORAL - 500MG;EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 850MG;EQ 15MG BASE, TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 15MG BASE, TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 30MG BASE, TABLET;ORAL - 1GM;EQ 50MG BASE, TABLET;ORAL - 500MG;EQ 50MG BASE, TABLET;ORAL - 500MG;1MG, TABLET;ORAL - 500MG;2MG

RELATED EXCIPIENT COMPANIES

2 Minakem, 4 Evonik, 8 Rochem International Inc, 22 SPI Pharma, 2 Seqens, 15 DKSH, 3 Jai Radhe Sales, 3 Pharm-RX Chemical, 10 Faran Shimi Pharmaceutical, 13 Boai NKY Pharmaceuticals Ltd, 1 Chynops Pharma, 16 Gangwal Healthcare, 12 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 1 ACG Worldwide, 12 Actylis, 3 Aeon Procare, 4 Alcedo Pharmachem, 10 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Avesta Pharma, 38 BASF, 1 Bioplus Life Sciences, 2 Clariant, 27 Corel Pharma Chem, 7 DFE Pharma, 1 Doshion Polyscience, 2 Finar, 13 Gangwal Chemicals, 1 Huzhou Sunflower Pharmaceutical, 7 Ideal Cures Pvt Ltd, 5 Ingredion Pharma Solutions, 39 Kerry, 5 Kima Chemical, 6 Lonza Capsugel, 5 Lubrizol Life Science Health, 22 Microlex e.U, 2 Nanjing Bold Chemical, 1 NEWEDGE Overseas, 2 Nomisma Healthcare, 5 Novo Excipients, 5 Pharmatrans-Sanaq, 12 Pluviaendo, 6 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 35 Roquette, 14 Seppic, 8 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 2 Shijiazhuang Huaxu Pharmaceutical, 12 Sigachi Industries, 4 The Dow Chemical Company, 3 Ulanqab Kema New Material, 3 Valens Pharmachem, 4 Vasa Pharmachem, 2 Vertellus, 2 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

128 Fillers, Diluents & Binders, 65 Coating Systems & Additives, 62 Direct Compression, 58 Controlled & Modified Release, 50 Thickeners and Stabilizers, 50 Disintegrants & Superdisintegrants, 47 Solubilizers, 41 Granulation, 39 Film Formers & Plasticizers, 38 Taste Masking, 36 Topical, 32 Lubricants & Glidants, 31 Parenteral, 24 Chewable & Orodispersible Aids, 23 Co-Processed Excipients, 15 Emulsifying Agents, 12 API Stability Enhancers, 10 Rheology Modifiers, 6 Surfactant & Foaming Agents, 5 Coloring Agents, 5 Empty Capsules, 4 Vegetarian Capsules, 1 Soft Gelatin

DIGITAL CONTENT

21 DATA COMPILATION #PharmaFlow, 360 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions, 505 Finished Drug Prices, 25 Annual Reports

MARKET PLACE

79 APIs, 51 FDF Dossiers

PATENTS & EXCLUSIVITIES

538 US Patents, 50 US Exclusivities, 17 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 3 USP, 11 Others

ANALYTICAL

2 BioAnalytical Methods, 1 Analytical Methods

$ Xls

Filters

01

Evonik

Germany

Pharmtech & Ingredients

Not Confirmed

Evonik's CDMO solutions for APIs and HPAPIs: It specializes where the client needs it most!

Dosage Form : Capsule, Tablet

Grade : Oral

Brand Name : EUDRAGIT® RL 100

Application : Controlled & Modified Release, Solubilizers

Excipient Details : EUDRAGIT® RL, an insoluble, highly permeable polymer used in combination with EUDRAGIT® RS in customized release drugs such as tablets, capsules, etc.

Pharmacopoeia Ref : NA

Technical Specs : Other grades- EUDRAGIT® RL 12,5, EUDRAGIT® RL 30 D, EUDRAGIT® RL PO

Ingredient(s) : Ammonia Methacrylate Copolymer Type A

Dosage Form : Capsule, Tablet

Grade : Oral

Evonik's CDMO solutions for APIs and HPAPIs: It specializes where the client needs it most!

Ingredient(s) : Ammonia Methacrylate Copolymer Type A

Dosage Form : Capsule, Tablet

Category : Controlled & Modified Release, Solubilizers

Brand : EUDRAGIT® RL 100

Applications : EUDRAGIT® RL, an insoluble, highly permeable polymer used in combination with EUDRAGIT® RS in customized release drugs such as tablets, capsules, etc.

Pharmacopoeia Ref : NA

Technical Specs : Other grades- EUDRAGIT® RL 12,5, EUDRAGIT® RL 30 D, EUDRAGIT® RL PO

Grade : Oral

02

Evonik

Germany

Pharmtech & Ingredients

Not Confirmed

Evonik's CDMO solutions for APIs and HPAPIs: It specializes where the client needs it most!

Dosage Form : Capsule, Tablet

Grade : Oral

Brand Name : EUDRAGIT® RS 100

Application : Controlled & Modified Release, Solubilizers

Excipient Details : EUDRAGIT® RS, a functional sustained release polymer, used in combination with EUDRAGIT® RL for customized release profiles in tablets, capsules, etc.

Pharmacopoeia Ref : NA

Technical Specs : Available as granules; Other grades- EUDRAGIT® RS 12,5, EUDRAGIT® RS 30 D, EUDRAGIT® RS PO

Ingredient(s) : Ammonio Methacrylate Copolymer Type B

Dosage Form : Capsule, Tablet

Grade : Oral

Evonik's CDMO solutions for APIs and HPAPIs: It specializes where the client needs it most!

Ingredient(s) : Ammonio Methacrylate Copolymer Type B

Dosage Form : Capsule, Tablet

Category : Controlled & Modified Release, Solubilizers

Brand : EUDRAGIT® RS 100

Applications : EUDRAGIT® RS, a functional sustained release polymer, used in combination with EUDRAGIT® RL for customized release profiles in tablets, capsules, etc.

Pharmacopoeia Ref : NA

Technical Specs : Available as granules; Other grades- EUDRAGIT® RS 12,5, EUDRAGIT® RS 30 D, EUDRAGIT® RS PO

Grade : Oral

03

Evonik

Germany

Pharmtech & Ingredients

Not Confirmed

Evonik's CDMO solutions for APIs and HPAPIs: It specializes where the client needs it most!

Dosage Form : Capsule, Granule / Pellet, Orodispersible Tablet, Powder, Tablet

Grade : Oral

Brand Name : EUDRAGIT® E 100

Application : Coating Systems & Additives, Controlled & Modified Release, Disintegrants & Superdisintegrants, Film Formers & Plasticizers, Taste Masking

Excipient Details : EUDRAGIT® E is an immediate-release polymer used as a taste masking & coating agent to improve swallowability of tablets, ODTs, capsules, powder, etc.

Pharmacopoeia Ref : NA

Technical Specs : Available as granules; Other grades- EUDRAGIT® E 12,5, EUDRAGIT® E PO.

Ingredient(s) : Amino Methacrylate Copolymer

Dosage Form : Capsule, Granule / Pellet, Orodispersible Tablet, Powder, Tablet

Grade : Oral

Evonik's CDMO solutions for APIs and HPAPIs: It specializes where the client needs it most!

Ingredient(s) : Amino Methacrylate Copolymer

Dosage Form : Capsule, Granule / Pellet, Orodispersible Tablet, Powder, Tablet

Category : Coating Systems & Additives, Controlled & Modified Release, Disintegrants & Superdisintegrants, Film Formers & Plasticizers, Taste Masking

Brand : EUDRAGIT® E 100

Applications : EUDRAGIT® E is an immediate-release polymer used as a taste masking & coating agent to improve swallowability of tablets, ODTs, capsules, powder, etc.

Pharmacopoeia Ref : NA

Technical Specs : Available as granules; Other grades- EUDRAGIT® E 12,5, EUDRAGIT® E PO.

Grade : Oral

04

Evonik

Germany

Pharmtech & Ingredients

Not Confirmed

Evonik's CDMO solutions for APIs and HPAPIs: It specializes where the client needs it most!

Dosage Form : Capsule, Tablet

Grade : Oral

Brand Name : EUDRAGIT® S 100

Application : Controlled & Modified Release

Excipient Details : EUDRAGIT® S 100, a delayed release polymer can be combined with other polymers for precise targeting and rapid drug release in tablets, capsules, etc.

Pharmacopoeia Ref : NA

Technical Specs : Available as powder; Other grades- EUDRAGIT® S 12,5

Ingredient(s) : Methacrylic Acid Copolymer Type B

Dosage Form : Capsule, Tablet

Grade : Oral

Evonik's CDMO solutions for APIs and HPAPIs: It specializes where the client needs it most!

Ingredient(s) : Methacrylic Acid Copolymer Type B

Dosage Form : Capsule, Tablet

Category : Controlled & Modified Release

Brand : EUDRAGIT® S 100

Applications : EUDRAGIT® S 100, a delayed release polymer can be combined with other polymers for precise targeting and rapid drug release in tablets, capsules, etc.

Pharmacopoeia Ref : NA

Technical Specs : Available as powder; Other grades- EUDRAGIT® S 12,5

Grade : Oral

Looking for Pharmaceutical Excipients offered by Evonik? Find Metformin Hydrochloride to address your drug delivery challenges on PharmaCompass.

Metformin Hydrochloride

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

105 API Suppliers

55 USDMF

41 CEP/COS

13 JDMF

28 EU WC

100 KDMF

38 NDC API

42 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

25 Drugs in Development

FINISHED DOSAGE FORMULATIONS

1812 FDF Dossiers

416 FDA Orange Book

545 Europe

120 Canada

102 Australia

137 South Africa

492 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 2.5MG BASE

TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 5MG BASE

TABLET, EXTENDED RELEASE;ORAL - 500MG;EQ 5MG BASE

TABLET;ORAL - 2.5MG;1GM

TABLET;ORAL - 2.5MG;500MG

TABLET;ORAL - 2.5MG;850MG

TABLET;ORAL - EQ 12.5MG BASE;1GM

TABLET;ORAL - EQ 12.5MG BASE;500MG

TABLET;ORAL - 1GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 625MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 750MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 850MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, EXTENDED RELEASE;ORAL - 150MG;1GM

TABLET, EXTENDED RELEASE;ORAL - 150MG;500MG

TABLET, EXTENDED RELEASE;ORAL - 50MG;1GM

TABLET, EXTENDED RELEASE;ORAL - 50MG;500MG

TABLET;ORAL - 1.25MG;250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 2.5MG;500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 5MG;500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, EXTENDED RELEASE;ORAL - 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, EXTENDED RELEASE;ORAL - 750MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

FOR SUSPENSION, EXTENDED RELEASE;ORAL - 500MG/5ML

TABLET, EXTENDED RELEASE;ORAL - 1GM

TABLET, EXTENDED RELEASE;ORAL - 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

SOLUTION;ORAL - 500MG/5ML

TABLET, EXTENDED RELEASE;ORAL - 1GM

TABLET, EXTENDED RELEASE;ORAL - 500MG

TABLET;ORAL - 500MG;EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 850MG;EQ 15MG BASE

TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 15MG BASE

TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 30MG BASE

TABLET;ORAL - 1GM;EQ 50MG BASE

TABLET;ORAL - 500MG;EQ 50MG BASE

TABLET;ORAL - 500MG;1MG

TABLET;ORAL - 500MG;2MG

RELATED EXCIPIENT COMPANIES

2 Minakem

4 Evonik

8 Rochem International Inc

22 SPI Pharma

2 Seqens

15 DKSH

3 Jai Radhe Sales

3 Pharm-RX Chemical

10 Faran Shimi Pharmaceutical

13 Boai NKY Pharmaceuticals Ltd

1 Chynops Pharma

16 Gangwal Healthcare

12 Nanjing Well Pharmaceutical

2 Pfanstiehl

1 ACG Worldwide

12 Actylis

TABLET;ORAL - 1GM Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 500MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 625MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 750MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 850MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 1.25MG;250MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 2.5MG;500MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 5MG;500MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, EXTENDED RELEASE;ORAL - 500MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, EXTENDED RELEASE;ORAL - 750MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, EXTENDED RELEASE;ORAL - 500MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 500MG;EQ 15MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons